Kenya: Kenya on Track in HPV Vaccination Despite Setbacks - CS Kariuki

[Nation] Kenya is on course in the immunisation of 800,000 girls against cervical cancer, Health Cabinet Secretary Sicily Kariuki has said, and allayed fears about the safety of the vaccine.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news

Related Links:

Publication date: Available online 4 December 2019Source: The Lancet Global HealthAuthor(s): Marc Arbyn, Elisabete Weiderpass, Laia Bruni, Silvia de Sanjosé, Mona Saraiya, Jacques Ferlay, Freddie BraySummaryBackgroundThe knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during th...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
CONCLUSION: This study highlighted the status of HPV vaccination and the prevalence of HPV-16/18 genotypes among HPV-infected women with abnormal cervical cytology according to HPV vaccination. It provides preliminary information regarding the status of HPV vaccination among Korean adult women. PMID: 31788994 [PubMed - as supplied by publisher]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
AbstractHuman papillomavirus (HPV) causes cervical carcinoma, which and is the third most common cancer, accounting for 275,000 deaths annually worldwide. Adjuvants have a key role in promotion of vaccine efficacy; therefore, using prophylactic and therapeutic vaccines combined with adjuvant could be of great benefit in prevention and treatment of cervical cancer. There are different types of adjuvants, including MF59TM adjuvants, RNA-based, JY (interleukin2/chitosan), cholera toxin (CT), heat-labile enterotoxin (LT), Freund ’s adjuvant, alum, SA-4-1BBL, λ-carrageenan (λ-CGN), heat shock proteins (HSPs)...
Source: Archives of Virology - Category: Virology Source Type: research
Authors: Giannella L, Delli Carpini G, Di Giuseppe J, Prandi S, Tsiroglou D, Ciavattini A Abstract Objective: The prevalence of some human papillomavirus (HPV) genotypes has been shown to change with age. So, also the distribution of HPV genotypes included in the nonavalent vaccine may not be the same at all ages, and this could mean that vaccine protection against cervical cancer may be affected by age. The present study aimed to evaluate whether there are age-related changes in the fraction of high-grade cervical intraepithelial neoplasia (CIN) attributable to HPV genotypes included in the nonavalent vaccine. ...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Conclusion: This cost-benefit analysis using limited available data indicates that massive HPV vaccination would not be cost-beneficial under the circumstances existing in 2016. Nevertheless, some indications point to the need for a re-assessment around 2020. This finding will inform public health decision-makers in Lebanon and similar neighbouring countries. PMID: 31774137 [PubMed - in process]
Source: Eastern Mediterranean Health Journal - Category: Middle East Health Tags: East Mediterr Health J Source Type: research
SummaryHuman papilloma virus (HPV) is a  DNA virus consisting of approximately 8000 base pairs. HPV represents the most common sexually transmitted infection worldwide. Around 200 different genotypes exist. They are distinguished into low- and high-risk genotypes, depending on the risk of such HPV-associated lesions undergoing malignant transformation. The high-risk genotypes include HPV 16 and 18, which are responsible for a variety of human cancers. The most common malignancies that are associated with HPV infection are cervical cancer, oropharyngeal cancer and anal cancer. Screening for HPV precursor...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: The immunogenicity of two-dose and three-dose HPV vaccine schedules, measured using antibody responses in young females, is comparable. The quadrivalent vaccine probably reduces external genital lesions and anogenital warts in males compared with control. The nonavalent and quadrivalent vaccines offer similar protection against a combined outcome of cervical, vaginal, and vulval precancer lesions or cancer. In people living with HIV, both the bivalent and quadrivalent HPV vaccines result in high antibody responses. For all comparisons of alternative HPV vaccine schedules, the certainty of the body of evidence ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
CONCLUSIONS: HPV testing of residual chlamydia specimens provides a simple, feasible method for monitoring circulating genotypes. Applied on a larger scale this method can be utilised to obtain a timely assessment of nonavalent vaccine impact among young women not yet eligible for cervical screening. PMID: 31767467 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
I am afraid for Dr. Tedros’ safety. The World Health Organization Director-General and I are walking from the WHO’s midtown-Manhattan offices to the nearby U.N. campus, where Tedros is participating in the U.N. General Assembly. As we cross avenues amid a chorus of honking horns, Tedros is so intent on answering my questions, rarely breaking eye contact, that he appears not to notice traffic lights changing and cyclists whizzing past at alarming proximity. His staff and I breathe a collective sigh of relief when he arrives at the U.N. unscathed. It should come as no surprise that the man at the helm of the worl...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized climate change health World Health Organization Source Type: news
While the HPV vaccines have been approved by the US FDA since 2006, in recent years an increasing number of women are living with cervical cancer globally. Among them, Chinese women have a higher cervical canc...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Study protocol Source Type: research
More News: African Health | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Girls | Kenya Health | Vaccines